Photo: Marko Bugarski / Unsplash
Company-reported topline data show a 7.6-point MADRS advantage over placebo at six weeks, alongside three treatment-related serious adverse events, including a suicide attempt.
Background
Helus Pharma, the company formerly known as Cybin, is developing HLP003, a deuterated form of psilocin, as an add-on treatment for major depressive disorder [2][3]. The drug has Breakthrough Therapy Designation from the U.S. Food and Drug Administration [2]. Current add-on treatment for depression relies mainly on atypical antipsychotics, which offer modest benefit and carry known risks such as weight gain, cardiometabolic problems and movement disorders [3].
APPROACH is the first of three studies in Helus's PARADIGM program. A second pivotal trial, EMBRACE, is underway, and EXTEND is a long-term extension study [2].
What Was Found
Helus announced topline APPROACH results on Nov. 16 [2]. The intent-to-treat population included 222 adults with major depressive disorder: 112 received HLP003 and 110 received placebo [2]. Participants needed a score of at least 24 on the Montgomery-Åsberg Depression Rating Scale (MADRS) at screening and baseline, and they stayed on a stable dose of their existing antidepressant throughout the study [2]. Mean baseline MADRS scores were 32.7 in the HLP003 group and 33.8 in the placebo group [2]. According to Fierce Biotech, patients received 16 mg of HLP003 or placebo on Day 1 and again three weeks later [4]. Pharmaphorum reported that the drug was taken by mouth in two supervised sessions [3].
At the primary endpoint at six weeks, MADRS scores fell by a least-squares mean of 19.5 points with HLP003 and 11.9 points with placebo. Helus reported a difference of 7.6 points (p<0.0001) [2]. The company said the gap appeared by Day 2, with a 5.0-point difference (p=0.0013), and held at Week 12, the key secondary endpoint, with a 7.0-point difference (16.9 vs. 9.9 points; p<0.0001) [2].
Helus reported response rates, defined as at least a 50% drop in MADRS score, of 56.3% for HLP003 versus 28.2% for placebo at Week 6. Remission rates, defined as a MADRS score of 10 or lower, were 50.9% versus 18.2% [2]. At Week 12, response rates were 45.5% versus 19.1% and remission rates 40.2% versus 15.5% [2]. Analysts had set a 5- to 6-point placebo-adjusted improvement as their benchmark, pharmaphorum reported [3].
Safety Questions and Limitations
The press release says HLP003 was "generally well tolerated." It says most adverse events were mild to moderate, transient and mainly confined to the day of dosing, that there were three HLP003 treatment-related serious adverse events, and that no new safety signals were identified [2]. The release does not describe those events [2].
STAT reported that the trial included serious adverse events that raise questions about the treatment's safety [1]. Pharmaphorum reported that the three treatment-related serious adverse events occurred in the HLP003 arm and included one suicide attempt by a participant whose depression had not responded to the drug [3]. The attempt occurred 55 days after the second dose. The patient was hospitalized two days after an overdose of their background antidepressant, which carries a boxed warning for suicidality, and was later discharged [3]. Fierce Biotech reported that the suicide attempt was disclosed on the company's investor call and that no serious adverse events occurred in the placebo arm [4]. The other two serious adverse events have not been described publicly in the sources VBN reviewed.
Chief medical officer Amir Inamdar said that, although suicidality is a feature of depression, the company "did not observe a signal of suicidality" with the drug after a comprehensive review of the data [3]. Helus shares fell about 11% after the readout, which pharmaphorum attributed to investor concern about safety [3].
These results come from a company press release and investor call. They have not been peer-reviewed or presented in full, and they lack complete adverse-event tables, discontinuation data by arm and suicidality rating-scale results. The release also does not report whether participants could tell which treatment they had received, a question often raised about psychedelic trials.
What Comes Next
Helus expects topline results from EMBRACE in the fourth quarter of 2027 [2], and the company hopes to seek approval in 2028 [3]. EXTEND is intended to provide data on long-term safety, durability and redosing [2]. A full account of the serious adverse events, in a peer-reviewed publication or a regulatory submission, will matter as much as the efficacy numbers.
This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician. If you or someone you know is in crisis, call or text 988 in the U.S.
References
Chen E. Helus' psychedelic drug improved depression in study but faces safety questions. STAT. Nov 16, 2026. https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/
Helus Pharma Inc. Helus Pharma announces positive topline results from Phase 3 APPROACH study evaluating HLP003 as adjunctive treatment in major depressive disorder. GlobeNewswire (via Finviz). Nov 16, 2026. https://finviz.com/news/423001/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder
Taylor P. Helus shares slide on psychedelic readout in depression. pharmaphorum. Nov 16, 2026. https://pharmaphorum.com/news/helus-shares-slide-psychedelic-readout-depression
Fierce Biotech. Helus' chemically modified psychedelic hits key goals in phase 3 depression trial. Fierce Biotech. Nov 2026. https://www.fiercebiotech.com/biotech/helus-touts-ph-3-win-its-chemically-modified-psychedelic-depression